Topical compositions comprising a corticosteroid
Topical compositions comprising a corticosteroid, at least one alcohol, and a penetration enhancing agent.
1. A method of treating moderate to severe plaque psoriasis in a subject in need thereof comprising topically administering to affected areas of the subject twice daily, for a period of up to two weeks, a topical cream composition comprising 0.025% (w/w) clobetasol, 3% cetostearyl alcohol, 6% of a mixture of glyceryl stearate and PEG 100 stearate, water, 3% diethylene glycol monoethyl ether, 1% white wax, 10% isopropyl myristate, and 5% cyclomethicone, wherein the clobetasol is the only active agent in the composition; and
wherein treating moderate to severe plaque psoriasis results in an investigator global assessment score of 0 to 1 and no clinically significant hypothalamic pituitary adrenal (HPA) axis suppression.
2. The method of claim 1 , wherein the clobetasol is clobetasol propionate.
3. The method of claim 1 , wherein the topical cream composition is substantially free of propylene glycol.
4. The method of claim 1 , wherein the topical cream composition has a viscosity of from about 0.1 cP to about 500 cP when measured by Brookfield viscometer Cap 2000+with spindle no. 1 at 530 rpm at 25° C.
5. The method of claim 1 , wherein the topical cream composition further comprises an excipient selected from group consisting of polyols, glycols, ethers, glycol ethers, esters, sulfoxides, fatty acids, fatty acid esters, essential oils, terpenes, terpenoids, PEGylated fatty acids, PEGylated fatty acid esters and mixtures thereof nitrogenous compounds, alkanones, organic acids, and combinations thereof, and wherein the glycol is not propylene glycol.
6. The method of claim 1 , wherein the topical cream composition further comprises an excipient selected from the group consisting of cetyl alcohol, paraffin, stearyl alcohol, white wax, wax cetyl esters, microcrystalline wax, anionic emulsifying wax, non-ionic emulsifying wax, yellow wax, castor oil, ceresin, cetostearyl alcohol, cyclomethicone, glyceryl behenate, hectorite, myristyl alcohol, cetylstearyl alcohol, triolein, lanolin, and combinations thereof.
7. The method of claim 1 , wherein the investigator global assessment score and the mean clobetasol plasma level are measured at day 15.
8. The method of claim 1 , wherein treating moderate to severe plaque psoriasis in the subject results in at least 70% of subjects not having hypothalamic pituitary adrenal (HPA) axis suppression.
9. The method of claim 1 , wherein treating moderate to severe plaque psoriasis in the subject results in at least 80% of subjects not having hypothalamic pituitary adrenal (HPA) axis suppression.
10. The method of claim 1 , wherein treating moderate to severe plaque psoriasis in the subject results in at least 90% of subjects not having hypothalamic pituitary adrenal (HPA) axis suppression.
11. The method of claim 1 , wherein the topical cream composition provides a mean clobetasol plasma level less than about 130 pg/mL.
12. The method of claim 1 , wherein the topical cream composition provides a mean clobetasol plasma level of less than 150 pg/ml.
13. The method of claim 1 , wherein the subject has moderate to severe plaque psoriatic lesions involving at least about 5% body surface area.
14. The method of claim 1 , wherein the subject has moderate to severe plaque psoriatic lesions involving at least about 10% body surface area.
15. The method of claim 1 , the water is at least 60% of the total weight of the composition.